SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. The vaccine is the first and currently only variant-adapted vaccine available as a booster dose for individuals 12 years and older that has been granted approval in Hong Kong, BioNTech said.
(Reporting by Kirsti Knolle; Editing by Miranda Murray)
BioNTech's COVID booster vaccine approved in Hong Kong for individuals from age 12
December 23, 2022 at 02:45 am EST
Share
BERLIN (Reuters) - BioNTech and its partner for China, Shanghai Fosun Pharmaceutical, were granted approval for their COVID-19 vaccine that is adapted for the BA.4 and the BA.5 subvariants of Omicron for people aged 12 and older in Hong Kong, the German company said on Friday.
Share
